Matera M G, Di Tullio M, Lucarelli C, Casale F, Calabria C, Lampa E, Indolfi P, Rossi F
Institute of Pharmacology and Toxicology, Faculty of Medicine and Surgery, Second University of Naples, Italy.
J Med. 1993;24(2-3):161-70.
The aim of this study was to evaluate the efficacy and safety of ondansetron, an antagonist of 5-hydroxytryptamine type 3 (serotonin 3) (5-HT3) receptors, in controlling nausea and vomiting induced by antineoplastic therapy in children affected by cancer. Six patients affected by nausea and vomiting due to antineoplastic drugs were treated with ondansetron (4 mg/m2). Urinary samples for the assay of serotonin and 5-hydroxy-indoleacetic acid (5-HIAA) were collected 24 hr before antineoplastic drug treatment, 24 hours after the start of antineoplastic therapy and, 24 hr after the start of ondansetron therapy. All patients were affected by nausea and vomiting within two to four hr after the antineoplastic treatment. Urinary concentrations of serotonin and 5-HIAA were higher and statistically significant (P < 0.01) with respect to basal values. Treatment with ondansetron significantly reduced the number of episodes of nausea and vomiting, as well as the urinary values for serotonin and 5-HIAA.
本研究的目的是评估5-羟色胺3型（血清素3）（5-HT3）受体拮抗剂昂丹司琼在控制癌症患儿抗肿瘤治疗引起的恶心和呕吐方面的疗效和安全性。6例因抗肿瘤药物引起恶心和呕吐的患者接受了昂丹司琼（4 mg/m2）治疗。在抗肿瘤药物治疗前24小时、抗肿瘤治疗开始后24小时以及昂丹司琼治疗开始后24小时采集尿液样本，用于检测血清素和5-羟吲哚乙酸（5-HIAA）。所有患者在抗肿瘤治疗后两到四小时内均出现恶心和呕吐。血清素和5-HIAA的尿液浓度高于基础值，且具有统计学意义（P < 0.01）。昂丹司琼治疗显著减少了恶心和呕吐的发作次数，以及血清素和5-HIAA的尿液值。
